Vaccine Information Statements (VIS) are information sheets produced by the Centers for Disease Control and Prevention (CDC) that explain to vaccine recipients, their parents, or their legal representatives both the benefits and risks of a vaccine.
Under the
National Childhood Vaccine Injury Act (NCVIA), federal law requires that VIS be handed out whenever certain vaccinations are given.
Instructions for the use of VIS and record-keeping can be viewed on the Centers for Disease Control & Prevention website. Providers should review current CDC
requirements for record-keeping. An optional consent form template is provided
as an addendum to each VIS below.
For all questions pertaining to the literature list or order form, please call Immunizations Unit at (800) 252-9152.
NOTE: Federal law allows for VIS to be used for six months after the release of a revised VIS, unless the CDC states the new VIS should be used immediately.
Table of Contents
A |
B |
C |
D |
E |
F |
G |
H |
I |
J |
K |
L |
M |
N |
O |
P |
Q |
R |
S |
T |
U |
V |
W |
X |
Y |
Z |
DTaP (Diphtheria, Tetanus, & Pertussis)
Vaccine Information Statements and Addendums Relating to the DTaP (Diphtheria, Tetanus, & Pertussis) vaccines
Stock Number |
Title |
Revision |
C-91 |
DTaP (Diphtheria, Tetanus, & Pertussis) Vaccine VIS: English (PDF)
|
08/06/2021 |
C-91-add |
DTaP (Diphtheria, Tetanus, & Pertussis) Vaccine VIS Addendum: English (PDF)
|
08/2021 |
C-91A |
DTaP (Diphtheria, Tetanus, & Pertussis) Vaccine VIS: Spanish (PDF)
|
08/06/2021 |
C-91A-sup |
DTaP (Diphtheria, Tetanus, & Pertussis) Vaccine VIS Addendum: Spanish (PDF)
|
08/2021 |
Haemophilus influenzae type b (Hib)
HPV (Human Papillomavirus) Vaccine
Inactivated Influenza VIS
Influenza (Flu) Vaccine (Live, Intranasal)
Japanese Encephalitis (IXIARO)
MMR Vaccine (Measles, Mumps, & Rubella)
Vaccine Information Statements and Addendums Relating to the MMR Vaccine (Measles, Mumps, & Rubella) (MMR)
Stock Number |
Title |
Revision |
C-92 |
MMR Vaccine (Measles, Mumps, & Rubella) VIS: English (PDF)
|
08/06/2021
|
C-92-add |
MMR Vaccine (Measles, Mumps, & Rubella) VIS Addendum: English (PDF)
|
08/2021 |
C-92A |
MMR Vaccine (Measles, Mumps, & Rubella) VIS: Spanish (PDF)
|
08/06/2021 |
C-92A-sup |
MMR Vaccine (Measles, Mumps, & Rubella) VIS Addendum: Spanish (PDF)
|
08/2021
|
MMRV Vaccine (Measles, Mumps, Rubella, & Varicella)
Vaccine Information Statements and Addendums Relating to the MMRV Vaccine (Measles, Mumps, Rubella, & Varicella) (MMRV)
Stock Number |
Title |
Revision |
C-115 |
MMRV Vaccine (Measles, Mumps, Rubella, & Varicella) VIS: English (PDF)
|
08/06/2021
|
C-115-add |
MMRV Vaccine (Measles, Mumps, Rubella, & Varicella) VIS Addendum: English (PDF)
|
08/2021 |
C-115A |
MMRV Vaccine (Measles, Mumps, Rubella, & Varicella) VIS: Spanish (PDF)
|
08/06/2021 |
C-115A-sup |
MMRV Vaccine (Measles, Mumps, Rubella, & Varicella) VIS Addendum: Spanish (PDF)
|
08/2021 |
Meningococcal ACWY Vaccine
Multiple Vaccines (DTap, HiB, Hepatitis B, Polio, and PCV13)
Pneumococcal Conjugate (PCV) Vaccine
Pneumococcal Polysaccharide (PPSV 23) Vaccine
Recombinant Zoster (Shingles) Vaccine
Td (Tetanus, Diphtheria) Vaccine
Tdap (Tetanus, Diphtheria, Pertussis) Vaccine
Vaccine Information Statements and Addendums Relating to the Tdap (Tetanus, Diphtheria, and Pertussis) vaccine
Stock Number |
Title |
Revision |
C-109 |
Tdap (Tetanus, Diphtheria, Pertussis) Vaccine VIS: English (PDF)
|
08/06/2021 |
C-109-add |
Tdap (Tetanus, Diphtheria, Pertussis) Vaccine VIS Addendum: English (PDF)
|
08/2021 |
C-109A |
Tdap (Tetanus, Diphtheria, Pertussis) Vaccine VIS: Spanish (PDF)
|
08/06/2021 |
C-109A-sup |
Tdap (Tetanus, Diphtheria, Pertussis) Vaccine VIS Addendum: Spanish (PDF)
|
08/2021 |